TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Solifenacin Succinate in a Flexible Dose Regimen With Simplified Bladder Training Versus Solifenacin Succinate in a Flexible Dose Regimen Alone in a Prospective, Randomized, Parallel Group, Overactive Bladder Symptom Study
Brief Summary: This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own. The study will compare the symptoms of OAB by assessing patient diaries and other patient reported outcomes.


Options:
A: Arm Label: Health education intervention (HEI); Type: EXPERIMENTAL; Interventions: Behavioral: Health education intervention (HEI) | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health education intervention (HEI); Assigned to Arm(s): Health education intervention (HEI)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Simplified bladder training | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Simplified bladder training; Assigned to Arm(s): 2
C: Arm Label: Tät®II Treatment app; Type: EXPERIMENTAL; Interventions: Device: Tät®II Treatment app | Arm Label: Tät®II Information app; Type: OTHER; Interventions: Device: Tät®II Information app | Intervention Type: DEVICE; Name: Tät®II Information app; Assigned to Arm(s): Tät®II Information app | Intervention Type: DEVICE; Name: Tät®II Treatment app; Assigned to Arm(s): Tät®II Treatment app
D: Arm Label: MyHealthebladder; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MyHealtheBladder | Arm Label: VA Video Connect; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: VA Video Connect | Intervention Type: BEHAVIORAL; Name: VA Video Connect; Assigned to Arm(s): VA Video Connect | Intervention Type: BEHAVIORAL; Name: MyHealtheBladder; Assigned to Arm(s): MyHealthebladder

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Solifenacin Succinate in a Flexible Dose Regimen With Simplified Bladder Training Versus Solifenacin Succinate in a Flexible Dose Regimen Alone in a Prospective, Randomized, Parallel Group, Overactive Bladder Symptom Study
Brief Summary: This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own. The study will compare the symptoms of OAB by assessing patient diaries and other patient reported outcomes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Simplified bladder training | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Simplified bladder training; Assigned to Arm(s): 2
B: Arm Label: Pelvic floor training; Type: ACTIVE_COMPARATOR; Interventions: Other: Pelvic floor training | Arm Label: Literature-only group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pelvic floor training; Assigned to Arm(s): Pelvic floor training
C: Arm Label: Postpartum pelvic floor muscle training; Type: EXPERIMENTAL; Interventions: Other: Postpartum pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Postpartum pelvic floor muscle training; Assigned to Arm(s): Postpartum pelvic floor muscle training
D: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
Brief Summary: This study will compare the effectiveness (how well the drug works) of aripiprazole with placebo (fixed dose) in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A3; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: B1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1, A2, A3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine (Zyprexa) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: olanzapine (Zyprexa); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
Brief Summary: This study will compare the effectiveness (how well the drug works) of aripiprazole with placebo (fixed dose) in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).


Options:
A: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A3; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: B1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1, A2, A3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B1
C: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.
Brief Summary: The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.


Options:
A: Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A
B: Arm Label: Sertindole; Type: EXPERIMENTAL; Interventions: Drug: Sertindole | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine | Intervention Type: DRUG; Name: Sertindole; Assigned to Arm(s): Sertindole | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 3
D: Arm Label: Lurasidone Open-Label Arm A; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm C; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Intervention Type: DRUG; Name: Lurasidone HCl; Assigned to Arm(s): Lurasidone Open-Label Arm A, Lurasidone Open-Label Arm B, Lurasidone Open-Label Arm C

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy (MEC)
Brief Summary: The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC). Patients receiving more then one cycle of chemotherapy may opt to participate in an optional second cycle during which the patient will receive the same antiemetic regimen as cycle 1, except that an IV formulation of aprepitant will be given in place of the oral formulation on study day one. Study drug administration on subsequent days will be given orally as in cycle 1.


Options:
A: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone, Drug: Palonosetron Hydrochloride, Other: placebo | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: APF530, Drug: dexamethasone, Other: placebo | Arm Label: Arm III; Type: EXPERIMENTAL; Interventions: Drug: APF530, Drug: dexamethasone, Other: placebo | Intervention Type: DRUG; Name: APF530; Assigned to Arm(s): Arm II, Arm III | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Arm I, Arm II, Arm III | Intervention Type: DRUG; Name: Palonosetron Hydrochloride; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I, Arm II, Arm III
B: Intervention Type: DRUG; Name: MK0869, aprepitant / Duration of Treatment: 3 days; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: ondansetron / Duration of Treatment: 4 days; Assigned to Arm(s): N/A
C: Arm Label: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Arm Label: Docetaxel/Casopitant; Type: EXPERIMENTAL; Interventions: Drug: Casopitant/Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel | Intervention Type: DRUG; Name: Casopitant/Docetaxel; Assigned to Arm(s): Docetaxel/Casopitant
D: Arm Label: 1; Type: OTHER; Interventions: Drug: aprepitant, Drug: Comparator: ondansetron, Drug: Comparator: dexamethasone, Drug: Comparator; Placebo (unspecified) | Arm Label: 2; Type: OTHER; Interventions: Drug: Comparator: ondansetron, Drug: Comparator: dexamethasone, Drug: Comparator: fosaprepitant dimeglumine, Drug: Comparator; Placebo (unspecified) | Intervention Type: DRUG; Name: aprepitant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: ondansetron; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: dexamethasone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: fosaprepitant dimeglumine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator; Placebo (unspecified); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator; Placebo (unspecified); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial Comparing Oral Conscious Sedation With Intravenous Conscious Sedation for First Trimester Surgical Abortion
Brief Summary: The main objective of this study is to determine the equivalency of oral conscious sedation and intravenous conscious sedation for first trimester surgical abortion. We hypothesize that oral conscious sedation will be equivalent to intravenous conscious sedation for pain control. Additional objectives include describing subject satisfaction with each method of pain control and characteristics of each method such as side effect profile, recovery room time, and postoperative pain.


Options:
A: Arm Label: Hydrocodone/acetaminophen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocodone/acetaminophen, Drug: Ibuprofen, Drug: Lorazepam, Drug: Lidocaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Ibuprofen, Drug: Lorazepam, Drug: Lidocaine | Intervention Type: DRUG; Name: Hydrocodone/acetaminophen; Assigned to Arm(s): Hydrocodone/acetaminophen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Hydrocodone/acetaminophen, Placebo | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Hydrocodone/acetaminophen, Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Hydrocodone/acetaminophen, Placebo
B: Arm Label: No music; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Music; Type: EXPERIMENTAL; Interventions: Other: iPod Nano digital music player | Intervention Type: OTHER; Name: iPod Nano digital music player; Assigned to Arm(s): Music
C: Intervention Type: DRUG; Name: oxycodone + lorazepam versus fentanyl + midazolam; Assigned to Arm(s): N/A
D: Arm Label: No Paracervical Block for Pain Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Paracervical Block | Arm Label: Paracervical Block for Pain Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Paracervical Block | Intervention Type: PROCEDURE; Name: Paracervical Block; Assigned to Arm(s): Paracervical Block for Pain Control | Intervention Type: PROCEDURE; Name: Sham Paracervical Block; Assigned to Arm(s): No Paracervical Block for Pain Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy
Brief Summary: The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.


Options:
A: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: MK0954, /Duration of Treatment : 5 Years; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator : atenolol /Duration of Treatment : 5 Years; Assigned to Arm(s): N/A
D: Arm Label: Chlorthalidone; Type: N/A; Interventions: Drug: Chlorthalidone | Arm Label: Amlodipine; Type: N/A; Interventions: Drug: Amlodipine | Arm Label: Lisinopril; Type: N/A; Interventions: Drug: Lisinopril | Arm Label: Doxazosin; Type: N/A; Interventions: Drug: Doxazosin | Intervention Type: DRUG; Name: Chlorthalidone; Assigned to Arm(s): Chlorthalidone | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Lisinopril | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine | Intervention Type: DRUG; Name: Doxazosin; Assigned to Arm(s): Doxazosin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Brief Summary: The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportive care alone (packed red blood cell (RBC) transfusions), for treating anemia according to label guidance in patients with metastatic breast cancer receiving standard chemotherapy.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: epoetin alfa + packed RBC transfusion | Arm Label: 002; Type: OTHER; Interventions: Other: Standard supportive care (packed RBC transfusion) | Intervention Type: OTHER; Name: Standard supportive care (packed RBC transfusion); Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: epoetin alfa + packed RBC transfusion; Assigned to Arm(s): 001
B: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
C: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azacitidine | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azacitidine, Drug: Epoetin beta | Intervention Type: DRUG; Name: Azacitidine; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Epoetin beta; Assigned to Arm(s): Arm B
D: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Convergence Insufficiency Treatment Trial (CITT)
Brief Summary: The purposes of the CITT are:

* To determine whether Home-based Pencil Push-up therapy, Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics or Office-based VT/Orthoptics more effective than placebo treatment, and whether there are differences between the three treatments in improving subject symptoms and signs.
* To evaluate whether improvements in outcome measures are still present after one year of observation.


Options:
A: Arm Label: Office-based verg/accomm therapy (OBVAT); Type: EXPERIMENTAL; Interventions: Procedure: Office-based vergence/accommodative therapy | Arm Label: Office-based placebo therapy (OBPT); Type: PLACEBO_COMPARATOR; Interventions: Procedure: Office-based vergence/accommodative therapy | Intervention Type: PROCEDURE; Name: Office-based vergence/accommodative therapy; Assigned to Arm(s): Office-based placebo therapy (OBPT), Office-based verg/accomm therapy (OBVAT)
B: Intervention Type: BEHAVIORAL; Name: Home-based Pencil Push-Up Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Office-based Vision Therapy/Orthoptics; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Placebo Office-based Vision Therapy/Orthoptics; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Pencil Push-ups; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Office-based Vision Therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Placebo Office-based Vision Therapy; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Base-in prism glasses for reading; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Placebo reading glasses; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Obesity - Programming by Infant Nutrition
Brief Summary: Primary hypothesis to be tested:

Early protein intake predicts infant growth and later risk of childhood obesity.

* Childhood obesity is a major public health problem and is an identified priority concern for the health care. Infants fed formula are more likely to become obese than breastfed infants. The higher protein content of infant formulae, compared with breast milk, could be a causal factor.
* The study will in a multicentre intervention trial on newborn infants investigate whether feeding infant formulae, which differ in their level of milk proteins, can influence the risk of later childhood obesity. The trial will take place in five countries with different habitual total protein intakes to increase the range of protein intakes
* The investigators will study body composition, hormonal status, protein metabolism and anthropometric markers of childhood obesity. The whole cohort will be followed up until age 18 years, to assess the long term impact on the prevalence of obesity.
* The investigators will explore the impact of consumer (parental) attitudes to, and perceptions of, different practices of infant feeding in relation to infant behaviour (satisfaction, crying, sleep duration). This consumer science information will help improve the understanding of consumer (infants and parents) acceptance of and preference for foods that contribute to healthy diets.
* If a relationship between early dietary protein intake and later childhood obesity risk is confirmed, it offers possibilities for the prevention of obesity, for improving advice given to parents and for developing nutritionally improved dietary products for infants.


Options:
A: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Drug: Glutamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Experimental Infant Formula; Type: EXPERIMENTAL; Interventions: Other: Experimental Infant Formula | Intervention Type: OTHER; Name: Experimental Infant Formula; Assigned to Arm(s): Experimental Infant Formula
C: Intervention Type: DRUG; Name: Parenteral Nutrition; Assigned to Arm(s): N/A
D: Arm Label: Lower protein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Higher protein formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Breastfed reference group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lower protein formula; Higher protein formula; Assigned to Arm(s): Higher protein formula, Lower protein formula

Answer: D